Skip to main content
Liminatus Pharma, Inc. logo

Liminatus Pharma, Inc. — Investor Relations & Filings

Ticker · LIMN ISIN · US53271X1081 US Manufacturing
Open in API
Filings indexed 84 across all filing types
Latest filing 2026-06-03 Share Issue/Capital Cha…
Country US United States of America
Listing US LIMN

About Liminatus Pharma, Inc.

http://liminatuspharma.com/

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing novel, immune-modulating cancer therapies. The company specializes in immuno-oncology and is pioneering the development of a second-generation CD47-blockade antibody. This therapeutic approach is designed to utilize the patient's immune system to target and destroy cancer cells. Its lead clinical candidate, IBA101, is a humanized anti-CD47 antibody being advanced toward clinical trials for the treatment of various cancers.

Recent filings

Filing Released Lang Actions
424B3
Share Issue/Capital Change Classification · 85% confidence The document is a Form 424B3 prospectus supplement to an S-1 registration statement for a securities offering by Liminatus Pharma, Inc. It amends and updates the terms of the new shares and warrants being issued (a capital raising transaction). This clearly falls under a share issuance/capital change announcement rather than a traditional annual or quarterly report. According to the definitions, this best matches “Share Issue/Capital Change” (SHA).
2026-06-03 English
FORM 8-K
Delisting Announcement Classification · 98% confidence The document is a Current Report on Form 8-K filed under Item 3.01 “Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,” detailing that the company’s securities will be delisted from Nasdaq. This matches the definition of a Delisting Announcement (DLST).
2026-05-27 English
FORM 8-K
Regulatory Filings
2026-05-20 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K - Liminatus Pharma, Inc. (0001971387) (Filer)
Annual Report
2026-03-31 English
8-K - LIMINATUS PHARMA, INC. (0001971387) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details an amendment to the company's bylaws regarding quorum requirements for stockholder meetings. It includes the text of the amendment and mentions that the amendment will be submitted for ratification at the next annual meeting. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The document is not a proxy solicitation or voting results announcement but rather a management or board action disclosure. Form 8-K filings with such content typically fall under Regulatory Filings (RNS) as they are general regulatory announcements that do not fit into more specific categories like MANG or CGR. The document length is about 5894 characters, which is sufficient for a substantive filing but does not contain financial data or detailed management discussion. Therefore, the best classification is Regulatory Filings (RNS).
2026-03-04 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.